Experimental study of gene therapy with angiostatin gene in pancreatic cancer.
OBJECTIVE
To study the effects of angiostatin(AS) gene mediated by liposome on human pancreatic cancer cell line SW1990.


METHODS
Angiostatin gene was cloned into the eukaryotic expression vector pRC/CMV. The recombinant of pRC/CMV-AS was introduced into the pancreatic cancer cell line, SW1990. The mechanism of anti-tumor was studied and tested.


RESULTS
The eukaryotic expression vector pRC/CMV-AS was identified by the restriction digest. pRC/CMV-AS was stably integrated into the target cells and expressed by Western blot and drug-sensitivity tests, and inhibited the vascular endothelial cells proliferation in vitro. In addition, the effects of the angiostatin vector on reducing the volume of tumors implanted in nude mouse models were also noted.


CONCLUSIONS
This study demonstrated that the recombinant pRC/CMV-AS mediated by liposome may play a potential role in the treatment of pancreatic cancer in the future.
Nie
Sheng-Li
SL
Department of Gastroenterology, Sun Yat-Sen Memorial Hospital, Medical College, Sun Yat-Sen University, Guangzhou 510120, China. victorynie@163.com
Yuan
Shi-Zhen
SZ
D020533:Angiogenesis Inhibitors / Q000235:genetics*; D043168:Angiostatins / Q000235:genetics*; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002196:Capillaries / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D045744:Cell Line, Tumor; D004730:Endothelium, Vascular / Q000473:pathology; D015870:Gene Expression; D015316:Genetic Therapy; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D010190:Pancreatic Neoplasms / Q000378:metabolism / Q000473:pathology / Q000628:therapy*
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D043168:Angiostatins